13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02644044January 201623/3/2015Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm StudyIntrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm StudyTo Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MSDrug: Intrathecal methotrexateTel-Aviv Sourasky Medical CenterNULLNot yet recruiting18 Years75 YearsBoth30Phase 0NULL
2EUCTR2007-001377-28-PT09/01/200925/08/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
3EUCTR2007-001377-28-DE01/09/200815/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
4EUCTR2007-001377-28-NL15/07/200829/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
5EUCTR2007-001377-28-AT26/06/200827/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-001377-28-FR11/06/200829/02/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
7NCT00344253March 200622/6/2006Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate UveitisA Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)Uveitis, Intermediate;Macular Edema;Multiple SclerosisDrug: Interferon beta;Drug: MethotrexateHeidelberg UniversitySerono GmbHCompleted18 YearsN/ABoth19Phase 3Germany
8EUCTR2004-004403-37-DE27/02/200628/10/2005Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur StandardtherapieA monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-StudieEine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur StandardtherapieA monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie Uveitis intermedia with inflammatory macula edema with or without associated Multiple SclerosisProduct Name: Rebif
INN or Proposed INN: Interferon beta-1a
Product Name: Rebif
INN or Proposed INN: Interferon beta-1a
Product Name: Metex
INN or Proposed INN: Methotrexat
Universitätsklinikum HeidelbergNULLNot RecruitingFemale: yes
Male: yes
34Phase 3Germany
9NCT00112034June 200327/5/2005AVONEX® Combination Trial - ACTA Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.Multiple Sclerosis, Relapsing-RemittingDrug: Methotrexate;Drug: IV methylprednisoloneBiogen IdecNULLCompleted18 Years55 YearsBoth350Phase 4United States
10NCT00037115May 200215/5/2002Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.Demyelinating Disorders;Multiple Sclerosis;Optic Neuritis;Myelitis;NeuritisDrug: interferon beta 1a;Drug: methotrexate;Drug: methylprednisoloneMidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteConsultants in NeurologyWithdrawn18 Years50 YearsAll0Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00037102July 200115/5/2002Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple SclerosisAn Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple SclerosisMultiple SclerosisDrug: interferon beta 1a;Drug: methotrexateMidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteConsultants in Neurology;BiogenCompleted18 Years60 YearsAll16Phase 4United States